139 related articles for article (PubMed ID: 33634987)
1. Forty-three key gene expressions involved in the effect of indoleamine 2,3-dioxygenase 1 expression on cancer prognosis may be a potential indoleamine 2,3-dioxygenase 1 inhibitor biomarker.
Li W; Guo L; Xing Z; Fang X; Liang H; Zhang S; Shi L; Kuang C; Shi L; Zheng Y; Hu Y; Yang Q
Clin Transl Med; 2021 Feb; 11(2):e330. PubMed ID: 33634987
[No Abstract] [Full Text] [Related]
2. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
3. Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration.
Liu XQ; Lu K; Feng LL; Ding M; Gao JM; Ge XL; Wang X
Leuk Lymphoma; 2014 Feb; 55(2):405-14. PubMed ID: 23682557
[TBL] [Abstract][Full Text] [Related]
4. Expression of Indoleamine 2,3-Dioxygenase Gene Is a Feature of Poorly Differentiated Non-muscle-invasive Urothelial Cell Bladder Carcinomas.
Hudolin T; Mengus C; Coulot J; Kastelan Z; El-Saleh A; Spagnoli GC
Anticancer Res; 2017 Mar; 37(3):1375-1380. PubMed ID: 28314306
[TBL] [Abstract][Full Text] [Related]
5. An overview on the methods of determining the activity of Indoleamine 2, 3-Dioxygenase 1.
Zhao Y; Wang B; Liu J; Sun P; Liu H
J Drug Target; 2019 Aug; 27(7):724-731. PubMed ID: 30215536
[TBL] [Abstract][Full Text] [Related]
6. Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer.
Zhang T; Tan XL; Xu Y; Wang ZZ; Xiao CH; Liu R
Chin Med J (Engl); 2017 Mar; 130(6):710-716. PubMed ID: 28303855
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature.
Sailer V; Sailer U; Bawden EG; Zarbl R; Wiek C; Vogt TJ; Dietrich J; Loick S; Grünwald I; Toma M; Golletz C; Gerstner A; Kristiansen G; Bootz F; Scheckenbach K; Landsberg J; Dietrich D
EBioMedicine; 2019 Oct; 48():341-352. PubMed ID: 31628024
[TBL] [Abstract][Full Text] [Related]
8. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.
Yue EW; Douty B; Wayland B; Bower M; Liu X; Leffet L; Wang Q; Bowman KJ; Hansbury MJ; Liu C; Wei M; Li Y; Wynn R; Burn TC; Koblish HK; Fridman JS; Metcalf B; Scherle PA; Combs AP
J Med Chem; 2009 Dec; 52(23):7364-7. PubMed ID: 19507862
[TBL] [Abstract][Full Text] [Related]
10. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.
Mitra D; Horick NK; Brackett DG; Mouw KW; Hornick JL; Ferrone S; Hong TS; Mamon H; Clark JW; Parikh AR; Allen JN; Ryan DP; Ting DT; Deshpande V; Wo JY
Oncologist; 2019 Jun; 24(6):e275-e283. PubMed ID: 30755500
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma.
Ben-Haj-Ayed A; Moussa A; Ghedira R; Gabbouj S; Miled S; Bouzid N; Tebra-Mrad S; Bouaouina N; Chouchane L; Zakhama A; Hassen E
Immunol Lett; 2016 Jan; 169():23-32. PubMed ID: 26608400
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2, 3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma.
Wang L; Ma Q; Li D; Mu S; Li Y; Wang Y; Shi P; Yu H; Gao C; Guo K; Zhang Z
Pathol Res Pract; 2018 Sep; 214(9):1309-1314. PubMed ID: 30029936
[TBL] [Abstract][Full Text] [Related]
14. Effect of Indoleamine 2,3 Dioxygenase Inhibitor on the Cytotoxic Activity of Tumour-infiltrating Lymphocytes.
Le Naour S; Knol AC; Pandolfino MC; Khammari A; Dréno B
Acta Derm Venereol; 2019 Nov; 99(12):1186-1187. PubMed ID: 31408178
[No Abstract] [Full Text] [Related]
15. The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma.
Seppälä M; Halme E; Tiilikainen L; Luukkainen A; Laranne J; Rautiainen M; Huhtala H; Paavonen T; Toppila-Salmi S
Acta Otolaryngol; 2016 Jul; 136(7):729-35. PubMed ID: 26982018
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2, 3-dioxygenase regulation of immune response (Review).
Wu H; Gong J; Liu Y
Mol Med Rep; 2018 Apr; 17(4):4867-4873. PubMed ID: 29393500
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein-Barr Virus.
Sawada L; Vallinoto ACR; Brasil-Costa I
Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944437
[TBL] [Abstract][Full Text] [Related]
19. Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.
Zhao Y; Wei L; Liu J; Li F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):77-93. PubMed ID: 31844921
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer.
Tsai YS; Jou YC; Tsai HT; Cheong IS; Tzai TS
Urol Oncol; 2019 Nov; 37(11):810.e17-810.e27. PubMed ID: 31253481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
